Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Aprea Therapeutics, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 12.59M shares outstanding
USAprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways.
The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Leadership
Oren Gilad
Co-Founder, Chief Executive Officer, President and Director
John Hamill
Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary
Andrea Epstein
Controller
Brian Wiley
Senior Vice President of Corporate Development & Strategy
Employees
8
Country
US
Sector
Healthcare
Website
aprea.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Duey Marc | Director | Grant/Award | 3.1K | -- | Jun 16, 2026 |
 Pamukcu Rifat | Director | Grant/Award | 3.1K | -- | Jun 16, 2026 |
 Seizinger Bernd R. | Director | Grant/Award | 3.1K | -- | Jun 16, 2026 |
| Duey Marc | Director | Grant/Award | 12.6K | -- | Jun 16, 2026 |
 BIZZARI JEAN-PIERRE | Director | Grant/Award | 12.6K | -- | Jun 16, 2026 |
 HENNEMAN JOHN B III | Director | Grant/Award | 12.6K | -- | Jun 16, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
AIGH Capital Management LLC · also on 13F· joint filing· may incl. warrants· filed Apr 2026 | 1.2M | 9.4% | 13G |
AIGH Capital Management LLC | 1.0M | 8.1% | 13F |
 Gilad Oren President/CEO, Director | 393.9K | 3.1% | FORM 4 |
Vestal Point Capital, LP | 350.0K | 2.8% | 13F |
SPHERA FUNDS MANAGEMENT LTD. | 270.0K | 2.1% | 13F |
 Duey Marc Director | 259.3K | 2.1% | FORM 4 |
Nantahala Capital Management, LLC | 205.8K | 1.6% | 13F |
RENAISSANCE TECHNOLOGIES LLC | 105.8K | 0.8% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 74.9K | 0.6% | 13F |
CITADEL ADVISORS LLC | 58.6K | 0.5% | 13F |
Insiders
- Duey MarcDirector
- Pamukcu RifatDirector
- Seizinger Bernd R.Director
- BIZZARI JEAN-PIERREDirector
- HENNEMAN JOHN B IIIDirector
- Peters RichardDirector
- Gruia GabrielaDirector
- Grissinger MichaelDirector
- Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr
- Gilad OrenPresident/CEO
based on 12.59M shares outstanding
US30d Avg
282.58K
60d Avg
231.60K
90d Avg
310.77K